RxDoctor Payments Data

Trevor Conklin

Optometrist · Oklahoma City, OKNPI 1649558321

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (54.1%), food and beverage and entertainment — rather than concentrated in one kind of arrangement. Coopervision Inc. accounts for 65.8% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $3,893 and has fallen 87.4% since, to $490 in 2025. Among optometrist clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,623in general payments, 2019–2025

Across 77 payments — averaging $86.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$4K
  • Alcon$990
  • Bausch & Lomb Americas Inc.$401
  • Optos, Inc.$389
  • ABB Con-cise Optical Group LLC$155
  • AbbVie$90
  • plus $241 from 6 others

What the payments were for

  • Speaking & faculty fees$3,58254%
  • Food & beverage$2,77242%
  • Entertainment$2684%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,623 in reported general payments places this provider in the 95th percentile of 714 optometrist providers in Oklahoma.

See all optometrist providers in Oklahoma

Medicare billing

Part B allowed, 2024
$41,153
Medicare patients
234
Services billed
457

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost17$6,294
VyzultaLatanoprostene Bunod14$3,514
Brinzolamide11$2,420
Travoprost11$1,531
Timolol Maleate45$852
Latanoprost95$850
Brimonidine Tartrate27$646
Prednisolone Acetate17$611
ErythromycinErythromycin Base48$587
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha11$135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$90$6,29417 claims
Bausch & Lomb Americas Inc.Vyzulta$401$3,51414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 714 optometrist providers in Oklahoma.

Other optometrist in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →